Literature DB >> 11698044

Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists.

G F Joos1, K O De Swert, R A Pauwels.   

Abstract

The tachykinins substance P and neurokinin A are contained within sensory airway nerves. Immune cells form an additional source of tachykinins in inflamed airways. Elevated levels of tachykinins have been recovered from the airways of patients with asthma and chronic obstructive pulmonary disease. Airway inflammation leads to an upregulation of tachykinin NK(1) and NK(2) receptors. Preclinical studies have indicated a role for the tachykinin NK(1), NK(2) and NK(3) receptors in bronchoconstriction, airway hyperresponsiveness and airway inflammation caused by allergic and nonallergic stimuli. Compounds that are able to block two or three tachykinin receptors hold promise for the treatment of airways diseases such as asthma and/or chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698044     DOI: 10.1016/s0014-2999(01)01323-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Peptides       Date:  2010-10-13       Impact factor: 3.750

2.  Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture.

Authors:  Gert Zimmer; Karl-Klaus Conzelmann; Georg Herrler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor.

Authors:  Nancy Walters; Theresa Trunkle; Michael Sura; David W Pascual
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Propofol preferentially relaxes neurokinin receptor-2-induced airway smooth muscle contraction in guinea pig trachea.

Authors:  Neil R Gleason; George Gallos; Yi Zhang; Charles W Emala
Journal:  Anesthesiology       Date:  2010-06       Impact factor: 7.892

6.  Expression and coupling of neurokinin receptor subtypes to inositol phosphate and calcium signaling pathways in human airway smooth muscle cells.

Authors:  Kentaro Mizuta; George Gallos; Defen Zhu; Fumiko Mizuta; Farida Goubaeva; Dingbang Xu; Reynold A Panettieri; Jay Yang; Charles W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-18       Impact factor: 5.464

7.  The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.

Authors:  Ralph A Tripp; Azzeddine Dakhama; Les P Jones; Albert Barskey; Erwin W Gelfand; Larry J Anderson
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands.

Authors:  Jonathan E Phillips; John A Hey; Michel R Corboz
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells.

Authors:  Nobuyuki Ebihara; Motoaki Nishikawa; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.211

10.  Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation.

Authors:  Katelijne O De Swert; Ken R Bracke; Tine Demoor; Guy G Brusselle; Guy F Joos
Journal:  Respir Res       Date:  2009-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.